Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is expected to outperform in the market with a $22 PT due to its strong pipeline of potential radiopharmaceuticals, most notably TLX591/592, and a current revenue source from US sales of Illuccix. Risks to this positive outlook include potential clinical and regulatory failures of its pipeline programs and potential delays in obtaining regulatory approvals. The valuation is based on a blended peer group multiple to projected sales in 2026 and a sum-of-parts valuation for its pipeline programs, with some risk-adjustments applied.

Bears say

Telix Pharmaceuticals is facing potential headwinds in revenue generation as their main product, Illuccix, is an imaging agent rather than a therapeutic agent. While their recent collaboration with Regeneron Pharmaceuticals may provide external validation of their R&D platform, the success of their pipeline drugs is still uncertain. The company also faces financial risks with the potential for upfront payments and milestones from the collaboration not materializing. Investors should exercise caution when considering this stock.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.